View Exam | PowerPak

1. Which of the following endotypes is associated with type 2 asthma?

A. Early-onset eosinophilic asthma B. Late-onset eosinophilic asthma C. Obesity-associated asthma D. Non-atopic asthma

2. Response to treatment is best predicted by which of the following?

A. Age B. Presence of atopy C. Smoking history D. Sputum eosinophils

3. The efficacy of anti-IL-13 and anti-IgE agents is predicted by which biomarker?

A. Blood eosinophils B. FeNO C. Periostin D. Sputum eosinophils

4. What is the cut-off value for sputum eosinophils in severe asthma?

A. 1% B. 2% C. 3% D. >3%

5. A 10-year-old girl has a history of severe asthma that includes two visits to the emergency department within the last 12 months. Her physician has ordered a blood draw, but her parents are not clear on why their daughter needs this done. How would you counsel her parents about the physician's request?

A. The results will help tailor therapy. B. The results will determine if she's a good candidate for a biologic agent, and if so, which one. C. The physician will explain why the tests were done when he sees the patient next. D. The tests are routine in this situation.

6. A 10-year old boy has a 5-year history of asthma, including 2 visits to the emergency department within the last 12 months. His baseline blood eosinophils are 170 cells/µL, FENO 28 ppb. His current asthma regimen includes ICS/LABA (Advair 500/50 mcg 1 puff twice daily) and montelukast 5 mg once daily at bedtime. His parents want to know if there are any other options to help control his symptoms. Which biologic would you discuss as an option for him?

A. Omalizumab B. Reslizumab C. Benralizumab D. Dupilumab

7. An 18-year old woman with a 12-year history of asthma is due to initiate treatment with dupilumab for her asthma, which is currently uncontrolled with repeated exacerbations. Her blood eosinophils are 525 cells/µl; periostin is 47 ng/ml; FeNO is 52 ppb. Her current medications include Advair 500/50 and montelukast 10 mg, and prednisone 10 mg every other day. She is not confident that this new agent will work. How would you reassure her that her symptoms are likely to improve with this treatment?

A. Biologics always work for severe asthma B. Her physician would not start her on a medication if it wasn't going to work C. She has had asthma since childhood D. Her blood eosinophil count and FeNO are both high

8. What is a key action the pharmacist can take to support adherence and optimal outcomes in patients with severe asthma who are using inhaled therapy?

A. Demonstrate proper device technique and utilize teach-back B. Direct them to an on-line video that demonstrates proper device technique C. Provide a handout of how to properly use the device D. Refer the patient to their physician for instruction on how to use an inhalation device

9. What are current recommendations about the appropriate duration of therapy and when to discontinue a biologic in patients with severe asthma?

A. Each agent should be used for at least 6 months B. The recommendations are unique for each biologic agent C. A 4-month trial is recommended D. It is left to the physician's discretion

10. What factors indicate that a patient with severe asthma is responding to a biologic agent?

A. The patient reports feeling better B. Exacerbations are reduced C. Exacerbations are eliminated and oral steroids are reduced D. No defined criteria have been developed

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following endotypes is associated with type 2 asthma?

2. Response to treatment is best predicted by which of the following?

3. The efficacy of anti-IL-13 and anti-IgE agents is predicted by which biomarker?

4. What is the cut-off value for sputum eosinophils in severe asthma?

8. What is a key action the pharmacist can take to support adherence and optimal outcomes in patients with severe asthma who are using inhaled therapy?

9. What are current recommendations about the appropriate duration of therapy and when to discontinue a biologic in patients with severe asthma?

10. What factors indicate that a patient with severe asthma is responding to a biologic agent?

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following endotypes is associated with type 2 asthma?

2. Response to treatment is best predicted by which of the following?

3. The efficacy of anti-IL-13 and anti-IgE agents is predicted by which biomarker?

4. What is the cut-off value for sputum eosinophils in severe asthma?

8. What is a key action the pharmacist can take to support adherence and optimal outcomes in patients with severe asthma who are using inhaled therapy?

9. What are current recommendations about the appropriate duration of therapy and when to discontinue a biologic in patients with severe asthma?

10. What factors indicate that a patient with severe asthma is responding to a biologic agent?

« Return to Activity

Customers who Purchased
this Activity also Purchased